Cannell Capital’s Gain Therapeutics GANX Stock Holding History

Cannell Capital’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,371	Closed	-$59.6K	–	73
2023 Q1	$59.6K	Hold	12,371	–	–	0.01%	67
2022 Q4	$38.7K	Hold	12,371	–	–	0.01%	74
2022 Q3	$40K	Buy	12,371 +9,620	+350%	+$36.1K	0.01%	75
2022 Q2	$10K	Buy	+2,751	New	+$9.49K	﹤0.01%	84

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Cannell Capital's GANX Position: Q2 2023 in Review

Cannell Capital sold out of Gain Therapeutics (GANX) in Q2 2023, closing a stake of 12,371 shares — an estimated $59.6K sold.

Cannell Capital first reported a position in GANX in Q2 2022 and held it in 4 quarters. The position peaked at $59.6K in Q1 2023. 24 funds tracked by Wall St. Rank hold GANX as of Q2 2023.

Cannell Capital reported no remaining Gain Therapeutics position as of Q2 2023 after selling out during the quarter.
Cannell Capital sold 12,371 Gain Therapeutics shares in Q2 2023, an estimated $59.6K.
Cannell Capital first reported a position in Gain Therapeutics in Q2 2022 and held it in 4 quarters.
Cannell Capital's Gain Therapeutics position peaked at $59.6K in Q1 2023.
24 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.